KR20200051778A - 인간 시토메갈로바이러스 면역원성 조성물 - Google Patents

인간 시토메갈로바이러스 면역원성 조성물 Download PDF

Info

Publication number
KR20200051778A
KR20200051778A KR1020207010481A KR20207010481A KR20200051778A KR 20200051778 A KR20200051778 A KR 20200051778A KR 1020207010481 A KR1020207010481 A KR 1020207010481A KR 20207010481 A KR20207010481 A KR 20207010481A KR 20200051778 A KR20200051778 A KR 20200051778A
Authority
KR
South Korea
Prior art keywords
hcmv
leu
antigen
immunogenic composition
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207010481A
Other languages
English (en)
Korean (ko)
Inventor
파스칼 샤욱스
라파엘라 두마스
쟝 핸슬러
실비 피숑
파비엔 피라스-두스
Original Assignee
사노피 파스퇴르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 파스퇴르 filed Critical 사노피 파스퇴르
Priority to KR1020247040905A priority Critical patent/KR20250006307A/ko
Publication of KR20200051778A publication Critical patent/KR20200051778A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020207010481A 2017-09-13 2018-09-11 인간 시토메갈로바이러스 면역원성 조성물 Ceased KR20200051778A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247040905A KR20250006307A (ko) 2017-09-13 2018-09-11 인간 시토메갈로바이러스 면역원성 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306179.7 2017-09-13
EP17306179 2017-09-13
PCT/EP2018/074369 WO2019052975A1 (en) 2017-09-13 2018-09-11 IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040905A Division KR20250006307A (ko) 2017-09-13 2018-09-11 인간 시토메갈로바이러스 면역원성 조성물

Publications (1)

Publication Number Publication Date
KR20200051778A true KR20200051778A (ko) 2020-05-13

Family

ID=60782111

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207010481A Ceased KR20200051778A (ko) 2017-09-13 2018-09-11 인간 시토메갈로바이러스 면역원성 조성물
KR1020247040905A Pending KR20250006307A (ko) 2017-09-13 2018-09-11 인간 시토메갈로바이러스 면역원성 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247040905A Pending KR20250006307A (ko) 2017-09-13 2018-09-11 인간 시토메갈로바이러스 면역원성 조성물

Country Status (12)

Country Link
US (4) US11524069B2 (enExample)
EP (1) EP3681534A1 (enExample)
JP (2) JP7770767B2 (enExample)
KR (2) KR20200051778A (enExample)
CN (1) CN111344009A (enExample)
AU (1) AU2018331874B2 (enExample)
BR (1) BR112020004747A2 (enExample)
IL (1) IL273120B2 (enExample)
MX (1) MX2020002810A (enExample)
SG (1) SG11202002174SA (enExample)
WO (1) WO2019052975A1 (enExample)
ZA (1) ZA202001561B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200051778A (ko) 2017-09-13 2020-05-13 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
US12290560B2 (en) * 2018-12-10 2025-05-06 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
KR20230097028A (ko) * 2020-10-28 2023-06-30 사노피 파스퇴르 Tlr4 효현제를 함유하는 리포좀, 이의 제조 및 용도
CN116617383A (zh) * 2022-02-14 2023-08-22 华中师范大学 一种基于铝佐剂的联合佐剂系统、疫苗制剂及其制备方法与应用
WO2024218752A1 (en) * 2023-04-21 2024-10-24 Instar Technologies A.S. Pharmaceutical composition for vaccination against cytomegalovirus infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US20020102562A1 (en) 1995-05-24 2002-08-01 Pasteur Merieux Serums Et Vaccines S.A. Recombinant CMV neutralizing proteins
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
CA2699756A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infection
CN105944095B (zh) 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
MA34802B1 (fr) 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène
NZ616304A (en) * 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
AU2013286093B2 (en) 2012-07-06 2018-01-04 Novartis Ag Complexes of cytomegalovirus proteins
CA2879577C (en) 2012-07-27 2021-08-03 City Of Hope An mva vaccine for delivery of a ul128 complex and preventing cmv infection
EP3269388A1 (en) * 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
EP3134117A1 (en) * 2014-04-23 2017-03-01 Institute for Research in Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
MX2016014660A (es) * 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
EP3347045A4 (en) * 2015-09-10 2019-08-28 City of Hope MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
KR102724939B1 (ko) * 2016-06-17 2024-11-01 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형
KR20200051778A (ko) 2017-09-13 2020-05-13 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물

Also Published As

Publication number Publication date
EP3681534A1 (en) 2020-07-22
WO2019052975A9 (en) 2020-04-09
ZA202001561B (en) 2021-07-28
RU2020113253A3 (enExample) 2021-11-17
US11524069B2 (en) 2022-12-13
US20210023202A1 (en) 2021-01-28
SG11202002174SA (en) 2020-04-29
WO2019052975A1 (en) 2019-03-21
NZ763438A (en) 2025-03-28
MX2020002810A (es) 2020-07-21
KR20250006307A (ko) 2025-01-10
US20200276301A1 (en) 2020-09-03
CN111344009A (zh) 2020-06-26
CA3075207A1 (en) 2019-03-21
US20250228933A1 (en) 2025-07-17
JP2024026160A (ja) 2024-02-28
US11207403B2 (en) 2021-12-28
IL273120A (en) 2020-04-30
RU2020113253A (ru) 2021-10-18
JP2020533354A (ja) 2020-11-19
IL273120B2 (en) 2023-10-01
IL273120B1 (en) 2023-06-01
BR112020004747A2 (pt) 2020-09-24
AU2018331874A1 (en) 2020-04-30
US20230277655A1 (en) 2023-09-07
AU2018331874B2 (en) 2022-06-02
JP7770767B2 (ja) 2025-11-17

Similar Documents

Publication Publication Date Title
US11207403B2 (en) Human cytomegalovirus immunogenic composition
US12421283B2 (en) Compositions and methods for treatment of cytomegalovirus
EP3247722B1 (en) Cytomegalovirus antigens and uses thereof
WO2012034025A2 (en) Human cytomegalovirus vaccine
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
KR20230054719A (ko) Sars-cov-2 감염에 대한 백신
KR20230058101A (ko) 토코페롤-함유 스쿠알렌 에멀젼 아쥬반트를 갖는 covid-19 백신
CA3075207C (en) Human cytomegalovirus immunogenic composition
RU2775424C2 (ru) Иммуногенная композиция цитомегаловируса человека
EP4401763A1 (en) Immunogenic compositions and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20260205

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2020 7010481

Appeal request date: 20241210

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101002574

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024101002574; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)